A Case of 5-Fluorouracil Induced Encephalopathy

被引:14
作者
Kwon, Kyung A. [1 ]
Kwon, Hyuk-Chan [1 ]
Kim, Min Chan [2 ]
Kim, Sung-Hyun [1 ]
Oh, Sung Yong [1 ]
Lee, Suee [1 ]
Kim, Hyo-Jin [1 ]
机构
[1] Dong A Univ, Dept Internal Med, Coll Med, Pusan 602715, South Korea
[2] Dong A Univ, Dept Surg, Coll Med, Pusan 602715, South Korea
来源
CANCER RESEARCH AND TREATMENT | 2010年 / 42卷 / 02期
关键词
5-FU; Neurotoxicity; Encephalopathy;
D O I
10.4143/crt.2010.42.2.118
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Patients with reduced dihydropyrimidine dehydrogenase (DPD) activity are at risk for experiencing serious adverse effects following 5-fluorouracil (5-FU) based chemotherapy. Neurotoxicity is considered an extremely rare side effect of 5-FU. We report here on an unusual case of 5-FU induced encephalopathy. A 38-year-old woman with advanced gastric carcinoma was treated with adjuvant chemotherapy that consisted of infused 5-FU (1,000 mg/m(2)) for 5 days and cisplatin (60 mg/m2) on day 1 following total gastrectomy. Nineteen days after starting chemotherapy, the patient displayed a sudden onset of slurred speech, confusion, cognitive disturbances and paranoia. A magnetic resonance image (MRI) of the brain showed no structural abnormalities, and the other laboratory tests provided no explanations for her symptoms, other than a slightly elevated ammonia level. The patient was treated with a lactulose retention enema and thiamine infusion, the 5-FU was halted and her symptoms then recovered after 7 days.
引用
收藏
页码:118 / 120
页数:3
相关论文
共 12 条
  • [1] Baek Jin Ho, 2006, Korean Journal of Internal Medicine, V21, P43
  • [2] Cheung WY, 2008, CURR ONCOL, V15, P234
  • [3] A Case of Wernicke's Encephalopathy Following Fluorouracil-based Chemotherapy
    Cho, In Jeong
    Chang, Hye Jung
    Lee, Kyoung Eun
    Won, Hye Sung
    Choi, Moon Young
    Nam, Eun Mi
    Mun, Yeung-Chul
    Lee, Soon Nam
    Seong, Chu-Myong
    [J]. JOURNAL OF KOREAN MEDICAL SCIENCE, 2009, 24 (04) : 747 - 750
  • [4] POPULATION STUDY OF DIHYDROPYRIMIDINE DEHYDROGENASE IN CANCER-PATIENTS
    ETIENNE, MC
    LAGRANGE, JL
    DASSONVILLE, O
    FLEMING, R
    THYSS, A
    RENEE, N
    SCHNEIDER, M
    DEMARD, F
    MILANO, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (11) : 2248 - 2253
  • [5] 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development
    Grem, JL
    [J]. INVESTIGATIONAL NEW DRUGS, 2000, 18 (04) : 299 - 313
  • [6] HEGGIE GD, 1987, CANCER RES, V47, P2203
  • [7] HEIER MS, 1989, ANTICANCER RES, V9, P1073
  • [8] Intermediate dose 5-fluorouracil-induced encephalopathy
    Kim, YA
    Chung, HC
    Choi, HJ
    Rha, SY
    Seong, JS
    Jeung, HC
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2006, 36 (01) : 55 - 59
  • [9] BIOCHEMICAL BASIS FOR FLUOROURACIL NEUROTOXICITY
    KOENIG, H
    PATEL, A
    [J]. ARCHIVES OF NEUROLOGY, 1970, 23 (02) : 155 - &
  • [10] Fluorouracil-induced neurotoxicity
    Pirzada, NA
    Ali, II
    Dafer, RM
    [J]. ANNALS OF PHARMACOTHERAPY, 2000, 34 (01) : 35 - 38